TIS 0.00% 0.0¢ tissue therapies limited

any updates on euro trials?, page-7

  1. TDA
    11,411 Posts.
    lightbulb Created with Sketch. 137
    Hey Mattkid76, that date he has put there is for complete data of the whole trial to be submitted for European Approval, get that, then we start to sell.

    In the meantime we will get regular updates as certain patients finish their 24 odd days of treatment, as has happened in the last one:

    13 July 2010
    Excellent Additional VitroGro Clinical Results & Completion of
    Commercial Scale Manufacturing

    A total of 22 chronic venous ulcer patients have now been treated with VitroGro for 24 days each in the Australian clinical trial under the supervision of Professor Michael Stacey.
    Statistical analysis of the results was performed by staff from the University of Western Australia.
    Some of the exceptional results from this 24-day human venous ulcer trial include:
    - Complete healing of 4 ulcers out of 22
    - Average reduction of ulcer area of 40% in 24 days
    - Statistical significance of p < 0.0001



    2 September 2010
    Exceptional VitroGro Clinical Results Continue

    Biomedical company, Tissue Therapies Limited (ASX: TIS) has today released
    outstanding results from an additional cohort of 5 chronic venous ulcer patients in the Australian human trial of VitroGro, bringing the Australian study total to 27 patients.



    30 September 2010
    More Excellent VitroGro Clinical Results

    The clinical results for a further 3 patients show:
    - Duration of these venous ulcers prior to treatment with VitroGro:
    1, 4, and 8 months
    - Healing achieved with 6 VitroGro treatments over 24 days:
    57%, 46% and 90%
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.